Ad
related to: simvastatin dangers in dogs treatment reviews and side effects
Search results
Results From The WOW.Com Content Network
They said that 21 million doses of Librela have been given out and the side effects have been minimal. So far the F.D.A. has brought their findings to attention of veterinarians and is now ...
Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly. [11] The Heart Protection Study evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol. In this trial ...
The duration of treatment is not limited, but the prescribing physician should reassess at regular intervals if continued treatment is still necessary. The principal overdose risk is blockage of intestine or stomach. Colestyramine may interfere in the absorption of fat-soluble vitamins such as vitamins A, D, E, and K. No special considerations ...
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.
Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred.
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
However, there are side effects such as nausea, vomiting, diarrhea and constipation and, for the injectibals, injection-side irritation, injury or discomfort. Often, these are mild and serious ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.